Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypercholesterolemia HELP
Based on 5,998 articles since 2008
||||

These are the 5998 published articles about Hypercholesterolemia that originated from Worldwide during 2008-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome]. 2016

Colivicchi, Furio / Gulizia, Michele Massimo / Arca, Marcello / Abrignani, Maurizio Giuseppe / Perna, Gian Piero / Mureddu, Gian Francesco / Nardi, Federico / Riccio, Carmine / Anonymous4200872. ·U.O.C. Cardiologia, Ospedale S. Filippo Neri, Roma. · U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania. · Centro Aterosclerosi, Policlinico Umberto I, Sapienza Università di Roma, Roma. · U.O.C. Cardiologia, Ospedale Civile Sant'Antonio Abate, Erice (TP). · U.O.C. Cardiologia, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Ancona. · U.O.C. Cardiologia, A.O. San Giovanni-Addolorata, Roma. · U.O.C. Cardiologia, Ospedale Castelli, Verbania. · U.O.C. Cardiologia e Riabilitazione Cardiologica, A.O. Sant'Anna e San Sebastiano, Caserta. · ·G Ital Cardiol (Rome) · Pubmed #27311088.

ABSTRACT: LDL-cholesterol (LDL-C) reduction after acute coronary syndromes (ACS) is associated with a significant reduction in ischemic recurrences. Accordingly, international guidelines recommend a reduction of LDL-C below 70 mg/dl in ACS patients. Such a result can be accomplished by using high intensity statins, possibly associated with ezetimibe in selected cases. This document outlines the management strategies that can be consistently implemented in clinical practice in order to achieve and maintain guideline-recommended therapeutic goals.

2 Guideline Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients. 2015

Kim, Bu Kyung / Kim, Hyeon Chang / Ha, Kyoung Hwa / Kim, Dae Jung. ·Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. · Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea. · Cardiovascular and Metabolic Disease Etiology Research Center, Ajou University School of Medicine, Suwon, Korea. · Cardiovascular and Metabolic Disease Etiology Research Center, Ajou University School of Medicine, Suwon, Korea. ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. ·J Korean Med Sci · Pubmed #26539005.

ABSTRACT: The American College of Cardiology and the American Heart Association (ACC/AHA) 2013 joint guidelines for the treatment of hypercholesterolemia expand the indications for statin therapy. This study was performed to estimate the numbers of diabetic patients indicated for statin therapy according to the Third Adult Treatment Panel (ATP-III) of the National Cholesterol Education Program guidelines and the new ACC/AHA guidelines in Korea. We analyzed the data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. Patients with diabetes over 30 yr of age were analyzed by the two guidelines. Of the total 1,975 diabetic patients, only 377 (19.1%) were receiving drugs for dyslipidemia. Among 1,598 patients who had not taken any medications for dyslipidemia, 65.6% would be indicated for statin therapy according to the ATP-III guidelines. When we apply the new guidelines, 94.3% would be eligible for statin therapy. Among the total diabetic patients, the new guidelines, compared with the ATP-III guidelines, increase the number eligible for statin therapy from 53.1% to 76.2%. The new guidelines would increase the indication for statin therapy for most diabetic patients. At present, many diabetic patients do not receive appropriate statin therapy. Therefore efforts should be made to develop the Korean guidelines and to ensure that more diabetic patients receive appropriate statin therapy.

3 Guideline The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know. 2014

Lim, Tanna H / Orija, Israel B / Pearlman, Brian L / Anonymous6310811 / Anonymous6320811. ·Department of Internal Medicine, Atlanta Medical Center, Atlanta, GA. tannalim@yahoo.com. · ·Postgrad Med · Pubmed #25387212.

ABSTRACT: The new American College of Cardiology/American Heart Association blood cholesterol guidelines of 2013 are the first major revision of cholesterol therapy guidance in over a decade. Commonly used low-density lipoprotein cholesterol (LDL-C) target goals have been abrogated in favor of intensity of statin therapy, more in line with data from randomized clinical trials. Four groups of adult patients have been identified from these studies who will most benefit from statins: patients with atherosclerotic cardiovascular disease (ASCVD); patients with primary elevations of LDL-C ≥ 190 mg/dL; diabetic patients between age 40 and 75 years without ASCVD whose LDL-C is between 70 and 189 mg/dL; and patients between age 40 and 75 years without ASCVD or diabetes with LDL-C between 70 and 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher. This last primary prevention group has engendered the most controversy because the newly recommended risk calculator may overestimate risk or the 7.5% threshold may be too low, thereby subjecting too many patients to statins unnecessarily. This review summarizes the latest guidelines and pertinent evidence, and provides case examples to help clinicians familiarize themselves with the new recommendations.

4 Guideline Cardiac risk factors: new cholesterol and blood pressure management guidelines. 2014

Anthony, David / George, Paul / Eaton, Charles B. ·Memorial Hospital of Rhode Island, 111 Brewster St., Pawtucket, RI 02903, USA. david_anthony@brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Paul-George@Brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Charles_Eaton@Brown.edu ·FP Essent · Pubmed #24936717.

ABSTRACT: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines depart from low-density lipoprotein (LDL) treatment targets and recommend treating four specific patient groups with statins. Statins are the only cholesterol-lowering drugs with randomized trial evidence of benefit for preventing atherosclerotic cardiovascular disease (ASCVD). The groups are patients with clinical ASCVD; patients ages 40 to 75 years with diabetes and LDL of 70 to 189 mg/dL but no clinical ASCVD; patients 21 years or older with LDL levels of 190 mg/dL or higher; and patients ages 40 to 75 years with LDL of 70 to 189 mg/dL without clinical ASCVD or diabetes but with 10-year ASCVD risk of 7.5% or higher. Ten-year ASCVD risk may be calculated using the Pooled Cohort Equations. The Eighth Joint National Committee (JNC 8) guidelines for blood pressure management recommend a blood pressure goal of less than 140/90 mm Hg for all adults except those 60 years or older. For the latter group, the JNC 8 recommends a systolic blood pressure goal of less than 150 mm Hg. In another notable change from prior guidelines, the JNC 8 recommends relaxing the systolic blood pressure goal for patients with diabetes and chronic kidney disease to less than 140 mm Hg from less than 130 mm Hg.

5 Guideline [New thought from American new guideline on the treatment of blood cholesterol]. 2014

Zhao, Shuiping / Peng, Daoquan / Yu, Bilian / Huang, Xiansheng / Hu, Dayi / Shi, Xubo. · ·Zhonghua Xin Xue Guan Bing Za Zhi · Pubmed #24735622.

ABSTRACT: -- No abstract --

6 Guideline New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. 2014

Klose, Gerald / Beil, Frank Ulrich / Dieplinger, Hans / von Eckardstein, Arnold / Föger, Bernhard / Gouni-Berthold, Ioanna / Heigl, Franz / Koenig, Wolfgang / Kostner, Gert M / Landmesser, Ulf / Laufs, Ulrich / Leistikow, Frank / März, Winfried / Noll, Georg / Parhofer, Klaus G / Paulweber, Bernhard / Riesen, Walter F / Schaefer, Jürgen R / Steinhagen-Thiessen, Elisabeth / Steinmetz, Armin / Toplak, Hermann / Wanner, Christoph / Windler, Eberhard / Anonymous6010787. ·Practice for Internal Medicine, Gastroenterology, Cardiology and Preventive Medicine, Bremen, Germany. · ·Wien Klin Wochenschr · Pubmed #24615676.

ABSTRACT: After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.

7 Guideline Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Goff, David C / Lloyd-Jones, Donald M / Smith, Sidney C / Blum, Conrad / Schwartz, J Sanford / Anonymous2930783. · ·Ann Intern Med · Pubmed #24474185.

ABSTRACT: DESCRIPTION: In November 2013, the American College of Cardiology and American Heart Association (ACC/AHA) released a clinical practice guideline on the treatment of blood cholesterol to reduce cardiovascular risk in adults. This synopsis summarizes the major recommendations. METHODS: In 2008, the National Heart, Lung, and Blood Institute convened the Adult Treatment Panel (ATP) IV to update the 2001 ATP-III cholesterol guidelines using a rigorous process to systematically review randomized, controlled trials (RCTs) and meta-analyses of RCTs that examined cardiovascular outcomes. The panel commissioned independent systematic evidence reviews on low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in secondary and primary prevention and the effect of lipid drugs on atherosclerotic cardiovascular disease events and adverse effects. In September 2013, the panel's draft recommendations were transitioned to the ACC/AHA. RECOMMENDATIONS: This synopsis summarizes key features of the guidelines in 8 areas: lifestyle, groups shown to benefit from statins, statin safety, decision making, estimation of cardiovascular disease risk, intensity of statin therapy, treatment targets, and monitoring of statin therapy.

8 Guideline 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Bairey Merz, C Noel / Blum, Conrad B / Eckel, Robert H / Goldberg, Anne C / Gordon, David / Levy, Daniel / Lloyd-Jones, Donald M / McBride, Patrick / Schwartz, J Sanford / Shero, Susan T / Smith, Sidney C / Watson, Karol / Wilson, Peter W F / Anonymous3630896. · ·J Am Coll Cardiol · Pubmed #24239923.

ABSTRACT: -- No abstract --

9 Guideline 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Bairey Merz, C Noel / Blum, Conrad B / Eckel, Robert H / Goldberg, Anne C / Gordon, David / Levy, Daniel / Lloyd-Jones, Donald M / McBride, Patrick / Schwartz, J Sanford / Shero, Susan T / Smith, Sidney C / Watson, Karol / Wilson, Peter W F / Eddleman, Karen M / Jarrett, Nicole M / LaBresh, Ken / Nevo, Lev / Wnek, Janusz / Anderson, Jeffrey L / Halperin, Jonathan L / Albert, Nancy M / Bozkurt, Biykem / Brindis, Ralph G / Curtis, Lesley H / DeMets, David / Hochman, Judith S / Kovacs, Richard J / Ohman, E Magnus / Pressler, Susan J / Sellke, Frank W / Shen, Win-Kuang / Smith, Sidney C / Tomaselli, Gordon F / Anonymous3680775. · ·Circulation · Pubmed #24222016.

ABSTRACT: -- No abstract --

10 Guideline [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis]. 2013

Anonymous2700775 / Xavier, H T / Izar, M C / Faria Neto, J R / Assad, M H / Rocha, V Z / Sposito, A C / Fonseca, F A / dos Santos, J E / Santos, R D / Bertolami, M C / Faludi, A A / Martinez, T L R / Diament, J / Guimarães, A / Forti, N A / Moriguchi, E / Chagas, A C P / Coelho, O R / Ramires, J A F. · ·Arq Bras Cardiol · Pubmed #24217493.

ABSTRACT: -- No abstract --

11 Guideline European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). 2012

Perk, Joep / De Backer, Guy / Gohlke, Helmut / Graham, Ian / Reiner, Zeljko / Verschuren, Monique / Albus, Christian / Benlian, Pascale / Boysen, Gudrun / Cifkova, Renata / Deaton, Christi / Ebrahim, Shah / Fisher, Miles / Germano, Giuseppe / Hobbs, Richard / Hoes, Arno / Karadeniz, Sehnaz / Mezzani, Alessandro / Prescott, Eva / Ryden, Lars / Scherer, Martin / Syvänne, Mikko / Scholte op Reimer, Wilma J M / Vrints, Christiaan / Wood, David / Zamorano, Jose Luis / Zannad, Faiez / Anonymous2630725 / Anonymous2640725. ·School of Health and Caring Sciences, Linnaeus University, Stagneliusgatan 14, Kalmar, Sweden. joep.perk@lnu.se · ·Eur Heart J · Pubmed #22555213.

ABSTRACT: -- No abstract --

12 Guideline [Recommendations for hypercholesterolemic children]. 2011

Luc, Gérald / Girardet, Jean-Philippe / Bruckert, Éric / Rieu, Daniel / Farnier, Michel / Darmaun, Dominique / Anonymous10730894 / Anonymous10740894. ·Nouvelle société française d’athérosclérose. gerald.luc@univ-lille2.fr · ·Presse Med · Pubmed #21391309.

ABSTRACT: Some of hypercholesterolemias observed in childhood have a high risk of premature cardiovascular diseases. The monogenic dominantly inherited hypercholesterolemias such as the familial hypercholesterolemia due to mutations on LDL receptor gene corresponds to these diseases. This article, jointly elaborated by the Nouvelle Société Française d’Athérosclérose together with the Nutrition committee of the Société Française de Pédiatrie, is to propose recommendations for a screening strategy and for management of hypercholesterolemia in children. The approach of these high-risk inherited hypercholesterolemia is specified and the dietary management, the indications and supervision of lipid lowering drug therapy in children are discussed.

13 Guideline [Recommendations for children with hypercholesterolemia]. 2011

Girardet, J-P / Luc, G / Rieu, D / Bruckert, E / Darmaun, D / Farnier, M / Anonymous2840681 / Anonymous2850681. ·Comité de nutrition de la Société française de pédiatrie, 75012 Paris, France. jean-philippe.girardet@trs.aphp.fr · ·Arch Pediatr · Pubmed #21145715.

ABSTRACT: Some cases of hypercholesterolemia observed in childhood present a high risk of premature cardiovascular disease, such as in monogenic dominantly inherited hypercholesterolemia, particularly familial hypercholesterolemia due to mutations on the LDL receptor gene. This article, jointly written by the Société Française de Pédiatrie Nutrition Committee and the Nouvelle Société Française d'Athérosclérose, proposes recommendations for a screening strategy and management of childhood hypercholesterolemia. A practical approach to high-risk cases of inherited hypercholesterolemia is detailed and the dietary management, indications, and supervision of lipid-lowering drug therapy in children are discussed.

14 Guideline [Expert recommendations on attaining the goal for treatment of hypercholesterolemia in clinical practice]. 2010

Anonymous3330666. · ·Zhonghua Xin Xue Guan Bing Za Zhi · Pubmed #20654070.

ABSTRACT: -- No abstract --

15 Guideline Best Practice Guidelines for treatment of hypercholesterolaemia: a statement from the Caribbean Cardiac Society. 2008

Chung, E E / Anonymous4730632. ·Caribbean Cardiac Society, The University of the West Indies, Kingston 7, Jamaica, West Indies. echung@mail.infochan.com · ·West Indian Med J · Pubmed #19565938.

ABSTRACT: There is an increase prevalence of chronic non-communicable diseases in the Caribbean as the region undergoes an epidemiologic transition from infectious to chronic non-communicable diseases. Numerous studies have identified hypertension, obesity, diabetes mellitus and hyperlipidaemia as risk factors for the development of coronary atherosclerosis. The Caribbean Cardiac Society recognizes that there is an increased prevalence of these disease entities and in an effort to foster best practice guidelines for the region, implemented a consensus conference for the discussion of hypercholesterolaemia, hypertension, diabetes mellitus and obesity in 2005. This statement outlines the recommendations of the consensus group of the Caribbean Cardiac Society on the Best Practice Guidelines for the therapy of hypercholesterolaemia.

16 Guideline Familial hypercholesterolaemia: summary of NICE guidance. 2008

Wierzbicki, Anthony S / Humphries, Steve E / Minhas, Rubin / Anonymous47760607. ·St Thomas' Hospital, London SE1 7EH. · ·BMJ · Pubmed #18753174.

ABSTRACT: -- No abstract --

17 Guideline Non-pharmacological control of plasma cholesterol levels. 2008

Poli, Andrea / Marangoni, Franca / Paoletti, Rodolfo / Mannarino, Elmo / Lupattelli, Graziana / Notarbartolo, Alberto / Aureli, Paolo / Bernini, Franco / Cicero, Arrigo / Gaddi, Antonio / Catapano, Alberico / Cricelli, Claudio / Gattone, Marinella / Marrocco, Walter / Porrini, Marisa / Stella, Roberto / Vanotti, Alfredo / Volpe, Massimo / Volpe, Roberto / Cannella, Carlo / Pinto, Alessandro / Del Toma, Eugenio / La Vecchia, Carlo / Tavani, Alessandra / Manzato, Enzo / Riccardi, Gabriele / Sirtori, Cesare / Zambon, Alberto / Anonymous1150592. ·Nutrition Foundation of Italy, Italy. · ·Nutr Metab Cardiovasc Dis · Pubmed #18258418.

ABSTRACT: The importance of non-pharmacological control of plasma cholesterol levels in the population is increasing, along with the number of subjects whose plasma lipid levels are non-optimal, or frankly elevated, according to international guidelines. In this context, a panel of experts, organized and coordinated by the Nutrition Foundation of Italy, has evaluated the nutritional and lifestyle interventions to be adopted in the control of plasma cholesterol levels (and specifically of LDL cholesterol levels). This Consensus document summarizes the view of the panel on this topic, with the aim to provide an updated support to clinicians and other health professionals involved in cardiovascular prevention.

18 Editorial PCSK9 inhibitors for hypercholesterolaemia. 2017

McGettigan, Patricia / Ferner, Robin E. ·William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK p.mcgettigan@qmul.ac.uk. · West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK. ·BMJ · Pubmed #28104607.

ABSTRACT: -- No abstract --

19 Editorial The medicalization of prevention: health promotion is more than a pill a day 2016

Binns, Colin / Howat, Peter / Smith, James / Jancey, Jonine. · ·Health Promot J Austr · Pubmed #28436641.

ABSTRACT: -- No abstract --

20 Editorial The complexities of homozygous familial hypercholesterolemia management. 2016

Gidding, Samuel S. ·Nemours Cardiac Center, Wilmington, DE, USA. ·Pediatr Transplant · Pubmed #27882690.

ABSTRACT: -- No abstract --

21 Editorial Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis. 2016

Krittanawong, Chayakrit / Kitai, Takeshi / Zhang, HongJu / Sun, Tao. ·Department of Internal Medicine, Icahn School of Medicine at Mount Sinai St' Luke and Mount Sinai West, Tenth Avenue, Suite 3A-09, New York, NY, 10019, USA. Chayakrit.Krittanawong@mountsinai.org.; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. Chayakrit.Krittanawong@mountsinai.org. · Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. · Division of Cardiovascular Disease, Department of Medicine, Mayo Clinic, Rochester, MN, USA. ·Cardiovasc Drugs Ther · Pubmed #27830381.

ABSTRACT: -- No abstract --

22 Editorial What Should Be the Screening Strategy for Familial Hypercholesterolemia? 2016

McCrindle, Brian W / Gidding, Samuel S. ·From the Labatt Family Heart Centre, the Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto (B.W.M.); and the Nemours Cardiac Center, A.I. DuPont Hospital for Children, Wilmington, DE (S.S.G.). ·N Engl J Med · Pubmed #27783919.

ABSTRACT: -- No abstract --

23 Editorial PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al. 2016

Stein, Evan A. ·Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA. esteinmrl@aol.com. ·Cardiovasc Drugs Ther · Pubmed #27669716.

ABSTRACT: -- No abstract --

24 Editorial Are Patients with Low Non-HDL Cholesterol "Non-responders" to Statin Therapy on Coronary Plaque Regression? 2016

Koba, Shinji. ·Department of Medicine, Division of Cardiology, Showa University School of Medicine. ·J Atheroscler Thromb · Pubmed #27397478.

ABSTRACT: -- No abstract --

25 Editorial Enough Evidence, Time to Act! 2016

Rodriguez, Fatima / Knowles, Joshua W. ·From Stanford University, Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, CA. · From Stanford University, Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, CA. knowlej@stanford.edu. ·Circulation · Pubmed #27358433.

ABSTRACT: -- No abstract --

Next